# US 2003/0215819 A1 · Compositions and methods for inferring a response to statin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215819 A1
- Document ID: US20030215819A1
- Status: Published application
- Kind: A1
- Application number: 10/188,359
- Filed: 2002-07-01
- Published: 2003-11-20
- Earliest claimed: 2001-06-29
- Inventors: Tony N. Frudakis
- Web page: https://patentgrep.com/patent/US20030215819A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for inferring a statin response of a human subject from a nucleic acid sample of the subject are provided, as are reagents such as oligonucleotide probes, primers, and primer pairs, which can be used to practice such methods. A method of inferring a statin response can be performed, for example, by identifying in a nucleic acid sample from a subject, a nucleotide occurrence of at least one statin response-related single nucleotide polymorphism (SNP) and/or at least one statin response-related haplotype in a cytochrome P450 gene and/or an HMG Co-A reductase gene.

## Claims

### Claim 1

A method for inferring a statin response of a human subject from a nucleic acid sample of the subject, the method comprising identifying, in the nucleic acid sample, at least one haplotype allele indicative of a statin response, wherein the haplotype allele comprises
a) nucleotides of the cytochrome p450 3A4 (CYP3A4) gene, corresponding to
i) a CYP3A4A haplotype, which comprises
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292}, and
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; or
ii) a CYP3A4B haplotype, which comprises
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292}, and
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; or
iii) a CYP3A4C haplotype, which comprises
nucleotide 425 of SEQ ID NO:10 {CYP3A4E3-5—249},
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292}, and
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; or
b.) nucleotides of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) gene, corresponding to:
i) an HMGCRA haplotype, which comprises
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472}, and
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320};
ii) an HMGCRB haplotype, which comprises
nucleotide 519 of SEQ ID NO:11 {HMGCRE5E6-3—283},
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320}, and
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18—99}; or
iii) an HMGCRC haplotype, which comprises
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320}, and
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18—99},
whereby the haplotype allele is associated with a decrease in total cholesterol or low density lipoprotein in response to administration of a statin to the subject, thereby inferring the statin response of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the haplotype allele comprises
a) a CYP3A4A haplotype alleles, a CYP3A4B haplotype allele, or a CYP3A4C haplotype allele;
b) an HMGCRA haplotype allele, or an HMGCRB haplotype allele; or
c) a combination of a) and b).

### Claim 3 (depends on 1)

The method of claim 1, comprising identifying a diploid pair of haplotype alleles.

### Claim 4 (depends on 3)

The method of claim 3, wherein the diploid pair of haplotype alleles comprises
a) a diploid pair of CYP3A4A haplotype alleles, CYP3A4B haplotype alleles, or CYP3A4C haplotype alleles;
b) a diploid pair of HMGCRA haplotype alleles, HMGCRB, or HMGCRC haplotype alleles; or
c) a combination of a) and b).

### Claim 5 (depends on 1)

The method of claim 1, comprising identifying at least one CYP3A4C haplotype allele and at least one HMGCRB haplotype allele.

### Claim 6 (depends on 1)

The method of claim 1, comprising identifying
a diploid pair of CYP3A4C haplotype alleles;
a diploid pair of HMGCRB haplotype alleles; or
a diploid pair of CYP3A4C haplotype alleles and a diploid pair of HMGCRB haplotype alleles.

### Claim 7 (depends on 6)

The method of claim 6, wherein the diploid pair of CYP3A4C haplotype alleles is ATGC/ATGC or ATGC/ATAC.

### Claim 8 (depends on 6)

The method of claim 6, wherein the diploid pair of HMGCRB haplotype alleles is CGTA/CGTA or CGTA/TGTA.

### Claim 9 (depends on 6)

The method of claim 6, wherein the diploid pair of CYP3A4C haplotype alleles is ATGC/ATGC, and wherein the diploid pair of HMGCRB haplotype alleles is CGTA/CGTA or CGTA/TGTA.

### Claim 10 (depends on 1)

The method of claim 1, wherein the statin is Atorvastatin or Simvastatin.

### Claim 11 (depends on 6)

The method of claim 6, wherein the diploid pair of CYP3A4C haplotypes alleles is a diploid pair of one minor and one major haplotype allele or a diploid pair of minor haplotype alleles.

### Claim 12 (depends on 6)

The method of claim 6, wherein the diploid pair of HMGCRB haplotype alleles is a diploid pair of major haplotype alleles or a diploid pair of minor haplotype alleles.

### Claim 13 (depends on 6)

The method of claim 6, wherein the diploid pair of CYP3A4C haplotype alleles is ATGC/ATGC, ATGC/ATAC, ATGC/AGAC, ATGC/AGAT, ATGC/ATAT, ATGC/TGAC or ATGT/AGAT.

### Claim 14 (depends on 6)

The method of claim 6, wherein the diploid pair of HMGCRB haplotype alleles is CGTA/CGTA, CGTA/TGTA, CGTA/CGCA, CGTA/CGTC, or CGTA/CATA.

### Claim 15 (depends on 1)

The method of claim 1, comprising identifying
a diploid pair of CYP3A4C haplotype alleles;
a diploid pair of HMGCRC haplotype alleles; or
a diploid pair of CYP3A4C haplotype alleles and a diploid pair of HMGCRC haplotype alleles.

### Claim 16 (depends on 15)

The method of claim 15, wherein the diploid pair of CYP3A4C haplotype alleles is ATGC/ATGC, and wherein the diploid pair of HMGCRC haplotype alleles is GTA/GTA.

### Claim 17

A method for inferring a statin response of a Caucasian subject from a nucleic acid sample of the subject, the method comprising identifying, in the nucleic acid sample, a diploid pair of alleles indicative of a statin response, wherein the diploid pair of alleles is identified for:
a) nucleotides of the cytochrome p450 3A4 (CYP3A4) gene, corresponding to a CYP3A4C haplotype, which comprises
nucleotide 425 of SEQ ID NO:10 {CYP3A4E3-5—249},
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292}, and
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; and
b.) nucleotides of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) gene, corresponding to an HMGCRB haplotype, which comprises
nucleotide 519 of SEQ ID NO:11 {HMGCRE5E6-3—283},
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320}, and
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18—99},
wherein the diploid pair of CYP3A4C haplotype alleles is ATGC/ATGC, ATGC/ATAC, ATGC/AGAC, ATGC/AGAT, ATGC/ATAT, ATGC/TGAC or ATGT/AGAT, and the diploid pair of HMGCRB haplotype alleles is CGTA/CGTA, CGTA/TGTA, CGTA/CGCA, CGTA/CGTC, or CGTA/CATA, and wherein the diploid pair of haplotype alleles is associated with a decrease in total cholesterol or low density lipoprotein in response to administration of Atorvastatin or Simvastatin to the subject, thereby inferring the statin response of the subject.

### Claim 18

A method for inferring a statin response of a human subject from a nucleic acid sample of the subject, the method comprising identifying, in the nucleic acid sample, a nucleotide occurrence of at least one statin response-related single nucleotide polymorphism (SNP) corresponding to
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320},
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292},
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76};
nucleotide 425 of SEQ ID NO:10 {CYP3A4E3-5—249},
nucleotide 519 of SEQ ID NO:11 {HMGCRE5E6-3—283}, or
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18—99},
whereby the nucleotide occurrence is associated with a decrease in total cholesterol or low density lipoprotein in response to administration of the statin, thereby inferring the statin response of the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one statin response-related single nucleotide polymorphism (SNP) corresponds to:
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292},
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; or
nucleotide 425 of SEQ ID NO:10 {CYP3A4E3-5—249}.

### Claim 20 (depends on 18)

The method of claim 18, wherein the at least one statin response-related single nucleotide polymorphism (SNP) corresponds to:
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320},
nucleotide 519 of SEQ ID NO:11 {HMGCRE5E6-3—283}, or
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18—99}.

### Claim 21 (depends on 18)

The method of claim 18, wherein the at least one statin response-related single nucleotide polymorphism (SNP) corresponds to:
nucleotide 1311 of SEQ ID NO:7 {CYP3A4E7—243},
nucleotide 808 of SEQ ID NO:8 {CYP3A4E10-5—292},
nucleotide 227 of SEQ ID NO:9 {CYP3A4E12—76}; and
nucleotide 425 of SEQ ID NO:10 {CYP3A4E3-5—249}.

### Claim 22 (depends on 18)

The method of claim 18, wherein the at least one statin response-related single nucleotide polymorphism (SNP) corresponds to:
nucleotide 1757 of SEQ ID NO:2 {HMGCRE7E11-3—472},
nucleotide 1430 of SEQ ID NO:3 {HMGCRDBSNP—45320},
nucleotide 519 of SEQ ID NO:11 {HMGCRE5E6-3—283}, and
nucleotide 1421 of SEQ ID NO:12 {HMGCRE16E18-99}.

### Claim 23 (depends on 21)

The method of claim 21, wherein the nucleotide occurrences comprise a minor allele of a CYP3A4C haplotype.

### Claim 24 (depends on 22)

The method of claim 22, wherein the nucleotide occurrences comprise a minor allele of a HMGCRB haplotype.
